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Abstract. Parkinson’s disease is a complex heterogeneous disorder with urgent need for disease-modifying therapies. Progress
in successful therapeutic approaches for PD will require an unprecedented level of collaboration. At a workshop hosted by
Parkinson’s UK and co-organized by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD) Consortiums,
investigators from industry, academia, government and regulatory agencies agreed on the need for sharing of data to enable
future success. Government agencies included EMA, FDA, NINDS/NIH and IMI (Innovative Medicines Initiative). Emerging
discoveries in new biomarkers and genetic endophenotypes are contributing to our understanding of the underlying pathophys-
iology of PD. In parallel there is growing recognition that early intervention will be key for successful treatments aimed at
disease modification. At present, there is a lack of a comprehensive understanding of disease progression and the many factors
that contribute to disease progression heterogeneity. Novel therapeutic targets and trial designs that incorporate existing and new
biomarkers to evaluate drug effects independently and in combination are required. The integration of robust clinical data sets is
viewed as a powerful approach to hasten medical discovery and therapies, as is being realized across diverse disease conditions
employing big data analytics for healthcare. The application of lessons learned from parallel efforts is critical to identify barriers
and enable a viable path forward. A roadmap is presented for a regulatory, academic, industry and advocacy driven integrated
initiative that aims to facilitate and streamline new drug trials and registrations in Parkinson’s disease.
Keywords: Data standards, privacy, data integration, collaboration, quantitative disease progression, regulatory science
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NIH National Institute of Health
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OPDC Oxford Parkinson’s Disease Centre
Parkinson’s UK Parkinson’s United Kingdom
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THIN The Health Improvement Network
INTRODUCTION
Parkinson’s disease (PD) is the second most common
neurodegenerative disease after Alzheimer’s disease
(AD) [1]. Primarily a disease of adults over the age
of 60 yrs who may also have other comorbidities,
about 4% of cases begin prior to the age of 50 [2].
Therapeutic goals for PD are based on symptomatic
relief, but halting or slowing the neurodegenera-
tive process and the prevention of long-term adverse
outcomes represent urgent unmet needs. Available
dopamine-based therapeutic strategies achieve the
reduction of motor symptoms, but do not significantly
impact on the numerous non-motor manifestations of
PD [3]. Fluctuation phenomena and dyskinesia remain
a challenge, particularly in long-term treatment [4]. It
is now recognized that the first signs of motor impair-
ment in PD (early motor PD) is preceded for many
years by pathologic changes (reduced dopamine nerve
terminal function) and a variety of other biomarker
changes including rapid eye movement (REM) sleep
behavioral disturbances, GI disturbances and olfactory
deficits.
A major challenge is our lack of understanding
of disease progression and heterogeneity. Despite the
many candidate disease modifying therapies tested to
date, there is a lack of retrospective learning from these
costly clinical trials. For example, analysis of the failed
PRECEPT study [5] illustrates that many subjects who
were enrolled did not have evidence of dopaminergic
deficit or disease progression and thus were unlikely
to have PD. At present, the field lacks a comprehen-
sive, standardized and integrated database of relevant
longitudinal studies and clinical trials in PD.
Big data analytics in healthcare has evolved sig-
nificantly as an innovative approach for providing
insight from very large data sets with the goal of
improving patient outcomes in clinical practice and
drug development. Other diseases have undergone
efforts to standardize and integrate relevant data,
which have advanced therapeutic trial designs and
enabled model-based drug development and person-
alized medicine strategies. Examples include: from
the oncology field, DataSphere [6], from Amyotrophic
Lateral Sclerosis (ALS), the PRO-ACT database [7, 8],
from Alzheimer’s disease, Critical Path Institute (C-
Path) Online Data Repository (CODR) [9]; and from
Multiple Sclerosis, the Multiple Sclerosis Outcomes
Assessment Consortium (MSOAC) database [10]. PD
stands to benefit from applying such learnings, par-
ticularly given the advances in our understanding of
these diseases and vast amounts of data not presently
available for broad use.
The future of open science is catalyzed by the
expanding landscape of precompetitive collaborative
consortia. The term ‘precompetitive’ refers to collab-
oration on projects of mutual benefit between diverse
stakeholders, including industry partners that may pro-
duce competing goods or commercial products later
in the R&D process. Precompetitive collaboration
improves the prospects of all stakeholders relative to
common challenges they face. It can also benefit the
public by reducing duplication of effort, increasing
the effectiveness of R&D investments, and establish-
ing common standards and resources. Consortia and
precompetitive collaborations are highlighted in the
recent Nature Reviews Drug Discovery issue dedi-
cated to US precompetitive consortia [11] (http://www.
nature.com/nrd/focus/consortia/index.html) and are
embraced in Europe through the Innovative Medicines
Initiative (IMI) [12, 13] with endorsement of public-
private partnerships [14].
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To begin developing a strategic framework focused
on data sharing as the path towards successful
drug development in Parkinson’s disease, Parkin-
son’s United Kingdom (Parkinson’s UK) convened a
meeting in London in May, 2014. Diverse stakehold-
ers included representatives from academia, patient
advocacy and charitable organizations, government
agencies, regulatory agencies and precompetitive con-
sortia. The goals of this meeting were to identify
questions that, if answered, could tangibly impact PD
drug development, explore how existing data might
provide answers to those questions, and identify the
barriers to using those data, with the goal of map-
ping out a path forward. In parallel with the above
efforts, notably, government agencies have also initi-
ated development of strategic recommendations that
are desperately needed to fill the gaps in PD research
and drug development. For example, in January, 2014
the National Institute on Neurologic Disorders and
Stroke (NINDS) convened an expert meeting aimed
at building consensus on research priorities for PD
across basic, clinical, and translational domains [15].
Big data was a key area of focus and a strategic priority
for the future. Recognizing that pooling and sharing
data is a costly endeavor that requires collaboration
from diverse stakeholders {e.g., [16]}, workshop par-
ticipants addressed impediments to data sharing and
potential solutions that have gained traction in other
fields. They also considered new data sources including
data collected from personal- and home-monitoring
devices, which may provide relevant measures of the
functional impairments associated with PD. Finally,
they mapped out plans for using these data to build
quantitative drug development tools through regula-
tory paths to increase the efficiency of clinical trials.
The following themes were identified as gaps in
the field and areas of focus during the Parkinson’s
UK/Coalition Against Major Diseases (CAMD) two-
day workshop:
• The need for regulatory approved endpoints, trial
designs, and modeling tools.
• Identification of indicators of very early dis-
ease state markers to foster development of
pre-symptomatic and potential neuroprotective or
neuromodulatory treatments.
• Development of reliable biomarkers to monitor
disease progression, particularly to assess agents
that may modify the course of the disease.
• Understanding disease subtypes to enable the
stratification of patients to allow for more efficient
clinical trials.
REVIEW OF DATA SOURCES (SEE
TABLE 1)
Information that could provide greater understand-
ing of how PD progresses across the trajectory of the
disease lies in large datasets collected in clinical and
observational studies over the past decades. Unfortu-
nately, these datasets are inherently complex in nature
and have been largely inaccessible to researchers,
thereby limiting innovative analyses and genera-
tion of new knowledge. Workshop participants thus
prioritized efforts to obtain access to and develop
a means of aggregating, comparing, and analyzing
such data. Existing datasets held by pharmaceuti-
cal companies as well as academic research groups
were targeted for inclusion with the aim of enabling
data-sharing of clinical, imaging, and biomarker data.
Other potential data sources include electronic med-
ical records and claims data from public and private
payers. Notably, the intent of this meeting was not to
catalogue and inventory all possible sources of PD data
globally. Rather, datasets owned by meeting partici-
pants that may be available for sharing were described
and discussed collectively, with the common goal of
integration for the future.
Pharmaceutical clinical data, Teva
Pharmaceuticals
Teva Pharmaceuticals plans to release treatment and
control arm data from two clinical trials: PRECEPT, a
trial of the kinase inhibitor CEP-1347, which enrolled
806 patients with early PD [17]; and ADAGIO (Atten-
uation of Disease progression with Azilect Given Once
Daily), a trial of rasagiline in early idiopathic PD that
enrolled 1176 participants [18]. Outcome measures in
PRECEPT included the Unified Parkinson’s Disease
Rating Scale (UPDRS) and -CIT SPECT imaging
of the dopamine transporter [5]. The trial terminated
early when pre-specified endpoints for futility were
reached; but the sponsor continued to follow subjects
with biomarker studies in the PostCEPT observational
study, now the largest cohort of PD patients actively
followed in North America. PostCEPT provided blood
samples for genetic studies and cell line repository and
conductedasubstudyof-synucleinandRNAbiomark-
ers. The ADAGIO study is a large randomized clinical
trialevaluatingtheeffectsofrasagaline inadelayedstart
design.Thesedata,available to theCAMDConsortium,
will support development of biomarkers and innovative
clinical trial modeling tools for paving the regulatory
route for Parkinson’s treatment.
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The Oxford Parkinson’s Disease Centre (OPDC)
Discovery cohort (http://opdc.medsci.ox.ac.uk) was
established in 2009 with funding from Parkinson’s UK
as a longitudinal study of 1000 early stage, population-
ascertained PD subjects recruited from the Thames
Valley, UK. Its primary goal is to investigate the earli-
est genetic, molecular, cellular, and neuronal pathways
affected in PD, and to identify novel biomarkers for
early diagnosis and prognostication. Data and tissue
collected from OPDC subjects include a wide range
of clinical motor, non-motor, and cognitive assess-
ments, serum, plasma, DNA and CSF samples, skin
biopsies with induced pluripotent stem cell generation,
and MRI brain studies [19–21]. Three hundred control
and 170 PD at-risk subjects have been recruited to the
Discovery cohort thus far, with 18-month longitudinal
follow-up now ongoing and guaranteed for a 10-year
observation period in the PD and PD at-risk groups.
The Tracking Parkinson’s Study - Parkinson’s
Repository of Biosamples and Networked Datasets
(PRoBaND)
PRoBaND has enrolled 2000 subjects with recent
onset, including 240 young onset patients, and is
enrolling840unaffectedsiblings from60active recruit-
ing centers (http://proband.org.uk/). In addition to
clinical, demographic, and genetic data, PRoBaND has
collected data on cognition, olfactory function, sleep,
autonomic function, quality of life, and environmen-
tal exposures. Investigators will be asking multiple
research questions, including comparing young and
recentonsetPD(e.g., progression, response to therapy),
definitionof subtypes (includinggenetics), and the rela-
tionship between non-motor and motor features.
Cambridgeshire Parkinson’s Incidence from GP to
Neurologist (CamPaIGN)
The CamPaIGN study collected a population-based
cohort of newly diagnosed PD cases in the county of
Cambridgeshire, UK over two-year period (Dec 2000-
Dec 2002), in order to estimate the incidence of PD
and parkinsonism in this region, and to characterize
the frequency and pattern of cognitive impairment in
a population-representative incident PD cohort [22].
The cohort has since been prospectively followed,
with 10-year data recently published [23]. Longitu-
dinal assessments have included standardized motor
assessments such as the UPDRS and Hoehn and Yahr
scale, neuropsychological assessments, and standard-
ized measures of mood, function and quality of life.
DNAsampleshavealsobeencollected.Thecohortcom-
prises142casesmeetingUKPDSBrainBankcriteriafor
PD. Following attrition due to death and loss to follow-
up, 49 remained at the 10-year timepoint. Follow-up is
ongoing, with 12-year data currently being collected.
Parkinsonism: Incidence and Cognitive
Heterogeneity in Cambridgeshire (PICNICS)
PICNICS is a sequential comparative incidence
study in the same Cambridgeshire population. Dur-
ing an extended recruitment period (2008–2013), 286
cases meeting UKPDS Brain Bank criteria idiopathic
PD were enrolled. Patients are being followed up at
18-month intervals with a more extended panel of
assessments than the CamPaIGN cohort, including the
revised Movement Disorders Society-UPDRS (MDS-
UPDRS) [24] and incorporating the Addenbrooke’s
Cognitive Examination Revised (ACE-R) into the cog-
nitive battery [25]. A subgroup of PICNICS subjects
are also enrolled in the Incidence of Cognitive Impair-
ment in Cohorts with Longitudinal Evaluation PD
(ICICLE-PD) study, which incorporates a number
of additional non-motor questionnaires, more exten-
sive neuropsychological testing, saccadometry, and
biomarker analysis [26]. The maximum duration of
follow-up of the PICNICS cohort is 72 months at the
time of this meeting.
The Parkinson Progression Marker Initiative
(PPMI) biomarker study
PPMI mimics the landmark Alzheimer’s Disease
Neuroimaging Initiative (ADNI) in terms of a focus
on standardizing protocols and providing the research
community with open access to data and biosamples.
At the time of the London meeting, over 180,000
data downloads and over 40 biological specimens
had been requested through the ADNI. Data col-
lected through the PPMI include clinical (motor
and non-motor, neurobehavioral/cognitive, autonomic,
olfaction, sleep), imaging (DaTscanTM, AV133, amy-
loid, DTI/RS MRI), and corresponding biological
samples (DNA, blood, CSF). The PPMI study pop-
ulation originally included 400 newly diagnosed and
unmedicated PD subjects as well as 200 age- and
gender-matched healthy controls, and 70 subjects
with a clinical diagnosis of PD but without evidence
of dopaminergic deficiency (SWEDD) by dopamine
transporter SPECT imaging [27]. Subsequently, three
other subgroups were added: 100 pre-motor, 500 sub-
jects with LRRK2 mutations, and 100 with-synuclein
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mutations (50 with PD and 50 unaffected family mem-
bers). There are also future plans to incorporate novel
data sources that include wearable sensors in PPMI.
Parkinson’s Study Group (PSG) and the University
of Rochester Center for Human Therapeutics
(CHET)
PSG is a network of 132 Parkinson centers in the
United States, Canada and Puerto Rico, created to
conduct clinical trials in a consistently rigorous man-
ner. PSG conducted the clinical trials that led to the
approval of five PD marketed drugs, as well as many
other trials conducted through the NIH Exploratory
Trials in PD (NET-PD). Data from PSG, NET-PD, and
the PPMI studies are managed by the Center for Human
Experimental Therapeutics (CHET) at the University
of Rochester. The CHET coordinating center currently
houses data from over 40 PD clinical studies enrolling
7000 PD participants as well as from observational
studies, including data from physician-rated clinical
scales such as the UPDRS, Mini-Mental State Exami-
nation (MMSE) and the Beck Depression Inventory, as
well as patient-reported outcomes data, imaging, lab-
oratory and biomarkers, genetics, and demographics.
The PSG hosts a list of data on the website, a short
narrative about what the study covers, and guidance on
how to access the data (http://www.parkinson-study-
group.org/). The review process is coordinated by the
Michael J Fox Foundation and any researcher can
apply. There have been over 200 publications result-
ing from the use of these data to date and future use
is encouraged, especially for modeling disease pro-
gression Data used in modeling is only about 20% of
the data available through the PSG, but additional data
sources are relevant for this purpose (Table 1). Mod-
eling and simulation are a key part of learning and
confirming drugs, doses and outcomes and should be
used to improve the design of clinical trials.
The National Institute of Neurological Disorders
and Stroke (NINDS) Parkinson’s Disease
Biomarkers Program (PDBP).
In November of 2012, NINDS launched a com-
prehensive PD biomarker initiative that focuses on
standardized protocols for biospecimen collection
(DNA, RNA, blood, and CSF) and longitudinal clin-
ical assessments (motor/non-motor, neurobehavioral,
cognitive, sleep, olfaction, family history and medica-
tions) for PD participants across the disease spectrum.
A standard set of clinical assessments and biosample
collections are made at six- and 12-month intervals. As
of May 2014, clinical, genetic and biomarker data from
618 cases and 310 age- and gender-matched healthy
controls were broadly available to the research com-
munity through the PDPB data management resource
(DMR). A subset of participants (290) will also
undergo MRI and 150 participants will undergo DTI
and fMRI analysis. Unique to the PDBP program is a
subset of participants who have been diagnosed with
Multisystem Atrophy (50 MSA), Progressive Supranu-
clear Palsy (50 PSP), and Essential Tremor (30 ET).
The overall target enrollment for the PDBP initiative
is 1500.
The PDBP DMR is the first database for Parkin-
son’s disease that brings together disparate types of
datasets (clinical, genetic, imaging and biomarker) and
biorepository information under one data resource for
querying and downloading of data and requesting of
related biosamples. Like ADNI and PPMI, the PDBP
also shares data internationally with academic and
industry investigators. As of May 2014, more than
1000 data downloads and over 1500 biosamples had
been requested.
Other potential data sources
Understanding PD progression will require integra-
tion of data not just globally, but also from more het-
erogeneous sources, including asymptomatic cohorts
suchasPREDICT-PDin theUK[28],EPIPARKinGer-
many[29], and theHonoluluAgingStudy[30];primary
and secondary care datasets (e.g., electronic medical
records); andcollectionsofbiological specimens. In the
UK, the Dementias Platform UK is aggregating data
from up to two million participants from existing cohort
studies, is establishing a network of access to electronic
medical records, and is enhancing UK Biobank with
very large programs of neuroimaging and biomarker
studies together with outcome data collected from med-
ical records. As the primary purpose of the Dementias
Platform UK (DPUK) will be to identify risk factors
and biomarkers and to enable and conduct experimental
medicine inprimarydementiaconditions,diseaseswith
dementiaasacomponent suchasPDandotherneurode-
generative disorders will be within sight of the DPUK
objectives. Data from consumer technologies such as
smartphones and wearable devices can capture infor-
mationaboutmotorsymptoms,sleeppatterns,andother
functionalbehavioralaspectsthatmayreflectearlysigns
ofPD.Suchdata includes that recorded in theJohnHop-
kins pilot study [31], the Oxford OPDC cohort, and as
part of UK Biobank. Other datasets from investigations
of exposure to pesticides or other environmental risk
factors could also be useful.
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DATA TRANSFERABILITY,
STANDARDIZATION AND INTEGRATION
While data sharing is widely acknowledged across
stakeholders as essential to scientific progress includ-
ing the development of new treatments for diseases
such as PD, technical and cultural roadblocks have
limited our ability to exploit the potential of these
vast and growing data resources. The main roadblocks
discussed were: data transferability, remote data acces-
sibility and privacy/consent issues, data remapping to
comprehensive standards, and data integration. Over
the past decade, data sharing models have emerged that
have begun to break down some of the barriers [16].
• ADNI, a public-private partnership created in 2003
to expedite drug development by standardizing
and validating imaging and other biomarkers for
Alzheimer’s disease. ADNI provides researchers
with open access to raw and processed imaging,
clinical, genomic, and biomarker data through the
Laboratory of Neuro Imaging (LONI) Imaging
Data Archive (IDA) at the University of South-
ern California. Open access has resulted in seven
million data downloads and 500 peer-reviewed
articles from researchers around the world [32].
However, with the increasing number of sophis-
ticated imaging protocols and the increased use
of genome sequencing, the amount of data col-
lected has increased exponentially, such that it has
become impractical to house all data at one site.
The Global Alzheimer’s Association Interactive
Network (GAAIN) is a federated cloud-enabled
platform for sharing and providing access to data
analytic tools (www.gaain.org). GAAIN now has
many contributors, including ADNI.
Lessons from ADNI relevant to the PD initiative
include the need to define the key scientific questions
to be answered, standardize data collection protocols,
build tools that are sophisticated and matched to the
data collected, maintain open communication with the
research community about their needs to predict future
needs; and anticipate what informatics tools/resources
will be needed to address new research questions. Sev-
eral platforms and networks recently established or in
development are positioned to address some of these
issues:
• The MRC Dementias Platform UK (DPUK) plans
to bring together 22 cohorts from across the UK,
including the UK Biobank, integrated into a single
informatics platform. DPUK also plans to develop
a readiness cohort with baseline imaging data as
well as amyloid, genetics discovery, and -omics
discovery cohorts.
• The European Medical Information Framework
(EMIF) is a five-year IMI with 56 partners in 14
European countries, established to make datasets
visible to researchers, to integrate research
cohorts for combined analysis, and to enable
re-use of medical and other data for research. IMI-
EMIF is establishing three broad approaches to
data reutilizing and sharing. Firstly, to make data
visible and potentially utilizable by researchers, it
has established a browser for meta-data or descrip-
tions of data types and rules of engagement across
cohorts with up to 50,000 or more participants
in Europe. Secondly, the program has begun to
harmonize data across diverse cohorts to gener-
ate meta-cohorts for combined analysis. Thirdly,
EMIF is establishing safe and secure platforms,
respecting local legislative, ethical and other data-
governance models, which enable networked or
distributed analysis of very large datasets includ-
ing a total of more than 50 million persons. The
primary datasets include deliberately different
types of studies and data sources to establish scal-
able solutions for data access and analysis. These
data sources include made-for-purpose, ADNI-
like biomarker studies such as AddNeuroMed
and DESCRIPA, large population-based epidemi-
ological cohorts now re-purposed or enhanced
for neurodegenerative or metabolic disease pur-
poses, and very large electronic medical records
databases such as The Health Improvement Net-
work (THIN), a UK dataset covering a total of
nearly four million active patients from more than
500 primary care physicians.
• Sage Bionetworks, a nonprofit biomedical
research organization, aims to create globally
integrated, open-source systems that will enable
investigators to leverage multi-dimensional data
to distill meaningful information related to
human health and disease. Sage is a partner in
the Common Mind Consortium, which generates
disease models for neuropsychiatric disease
by bringing together large, well curated brain
samples and data management and analysis
expertise to enable integrated analysis of molec-
ular, genomic, and disease data. In partnership
with the Global CEO Initiative on Alzheimer’s
disease, Sage has also launched big data chal-
lenges to the AD research community, seeking
to leverage open source biomarker, cognitive,
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genetic, and demographic data from ADNI, Rush
University Medical Center, and the European
AddNeuroMed study to create a roadmap of AD
predictive biomarkers. In the PD arena, Sage
is partnering with the patient network Patients-
LikeMe (http://www.patientslikeme.com) to
combine patient-reported information with data
collected from the phone-based voice recordings.
The goal is to identify PD-related voice impair-
ments that may be useful in tracking disease
progression and response to therapy.
Integrating data across diverse domains and data
generators requires the application of commonly used
data standards. In support of the PDBP, NINDS devel-
oped a set of common data elements (CDEs) in 2010
for use in the PDBP data repository, along with a data
dictionary and analytic tools, to enable data compari-
son and meta-analyses across studies. NINDS plans to
capture legacy data from the Morris K. Udall Centers
of Excellence for Parkinson’s Disease and NINDS-
sponsored PD clinical trials.
C-Path and NINDS worked with industry partners
and the Clinical Data Interchange Standards Con-
sortium (CDISC, www.cdisc.org) to transform these
CDEs into global standards for collection of PD clin-
ical trials data. The FDA has recognized that CDISC
standards will be required, beginning in 2017, for reg-
ulatory submissions to facilitate efficient review of
medical products [33]. The CDISC standards will be
updated as new concepts or information important to
PD drug development are identified.
BARRIERS TO DATA SHARING AND
INTEGRATION (SEE TABLE 2)
Some of the challenges to data sharing and integra-
tion include lack of patient consent, diversity of data
formats in legacy data, legal concerns, patient privacy
issues, protecting the interests of junior researchers and
PhD students who have contributed to the data collec-
tion, given the current academic reward systems that
may not reward collaboration and sharing of data, and
possible conflict between individual and consortium
study group goals and achievements [6]. However,
data sharing between study groups has become rou-
tine in large scale genetics studies, e.g., the Structural
Genomics Consortium, a public-private partnership
that supports the discovery of new medicines through
open access research (http://www.thesgc.org). Dif-
ferent data-sharing models have been successfully
pursued, e.g., a common data repository with con-
trolled access or collaborative access with specific
summary data being released by specific study investi-
gators that are then incorporated into a meta-analytical
framework. It is important to differentiate between
studies that have been designed from their outset to be
open-access and for which participants were clearly
informed, and those that are led by a specific aca-
demic group or company with the potential for external
Table 2
Issues and potential paths to enable data sharing in PD
Issues/challenges Possible Solutions
Different formats of data Implementation of data standards
Country focused initiatives at present Implementation of global PPPs and consortia
Regulatory landscape–need for biomarkers Regulatory endorsement of drug development tools
Need for reliable longitudinal data Funding streams for high quality observational studies
Approval to access varied patient level datasets Data sharing initiatives through global PPPs and consortia
Cost for establishing and especially Business case for funding streams from government,
maintaining global database non-profit and private sectors
Privacy protection Adherence to patient privacy regulations and
de-identification of patient-level data
Patient consent for sharing Implementation of broad informed consent
documents in line with national guidelines
Incentives for data contributors Immediate access to integrated databases to further research
Recognition for data contributors Coauthorship and widespread dissemination
Data access and sharing Publication strategy and dissemination mechanism
Infrastructure needed for future sustainability Self sustained consortia based models and infrastructure
Alignment across consortia Focus on synergistic research areas and regulatory alignment
Define incentives for industry Derisking of drug development programs
through impact on regulatory science
Improved drug safety Reporting and monitoring of drug adverse effects
Impact on patients and families Rewarding in advancing the cause for all,
altruistic to others and for self
Young investigators to benefit Accelerate pathway for advanced degrees and training
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collaboration. An additional consideration is whether
studies are historical and no further follow-up is envis-
aged (closed) or whether data are from prospective
cohorts with future collection rounds where it is essen-
tial that no actions are taken that could harm future
cohort retention (open).
A survey of Parkinson’s UK members reported that
the vast majority of people with PD were eager for
their data to be accessed and made available to advance
research and therapeutic development. Barriers such
as informed consent will be addressed in diverse fora
e.g., universal Institutional Review Board (IRB) for
neurodegeneration, Sage Bionetworks portable con-
sent. Focused attention on issues of data sharing has
been the subject of numerous fora. This is clearly an
evolving concern in research, industry and regulatory
settings.
QUANTITATIVE DRUG DEVELOPMENT
PLATFORMS ENABLE MODELING OF
DISEASE PROGRESSION
There is growing recognition of the heterogene-
ity of PD based on advances in genetics, biomarkers,
pathology and diversity of clinical phenotypes. A quan-
titative, data-driven understanding of PD progression
is key to advancing a personalized medicine approach
to successful treatments. Modeling multiple sources of
variability in heterogeneous populations could provide
a valuable platform to support improved clinical trials,
including developing enrichment strategies and sim-
ulating different trial designs. Indeed, modeling and
simulation tools have been endorsed by the FDA as a
means of assessing the value of different trial designs to
detect disease modifying effects of treatments in early
stage PD [34].
CAMD developed and gained regulatory insight and
endorsement from both FDA and EMA for such a
model-based drug development tool for AD [9]. The
CAMD AD clinical trial simulation tool was designed
to understand and optimize clinical trial design for mild
to moderate AD based on a disease-drug model that
incorporates a quantitative understanding of disease
progression, drug effects, dropout rates, placebo rates,
and sources of variability [9]. Data used to develop
this tool came from patient-level data from clinical
trials and observational studies, and summary-level
data from the literature. The CAMD AD clinical trial
database consists of placebo arm data from 6500 AD
patients from global clinical trials and can be accessed
by researchers for broad applications [33]. Regulatory
endorsement of the AD clinical trial simulation tool
[35] demonstrates regulators’ support for such tools to
optimize trial design.
From a regulatory perspective, data sharing is
important for transparency, reproducibility, and iden-
tification of new information via analysis with the
purpose of answering broad ranging drug development
questions. FDA recognizes that analysis of multi-
ple clinical and/or pre-clinical data sets provides an
opportunity to advance drug development [36]. EMA
and FDA are aiming to align on regulatory processes
and guidance, where possible. At present, there is no
regulatory-defined concept of prodromal PD as a tar-
get population for drug approvals yet data in the future
may impact this path, as has been the case with AD.
PROPOSED ROADMAP FOR A
MODEL-BASED CLINICAL TRIAL
ENRICHMENT PLATFORM FOR
EARLY PD
Personalized medicine strategies enable treatments
that target the right therapy to the right patient at the
right time. Enriching trials for subjects likely to show
clinical benefit has been endorsed by both the FDA
and EMA as a means of increasing the efficiency of
those trials [37, 38]. To date, trials in PD have typically
recruited all subjects that meet historically defined
diagnostic criteria for the disease. Yet at present, diag-
nostic criteria for PD are being redefined [24, 39, 40]
and there is an urgent need to identify subsets of PD
patients with defined disease trajectories. Regulatory
endorsement of modeling and simulation tools in a
defined context of use, serves to de-risk drug devel-
opment in design of trials and streamline the review
of new drug candidates through a regulatory endorsed
model that applies across therapeutic targets and can be
utilized by multiple sponsors. Figure 1 illustrates how
available data might be applied to the development
of a model-based clinical trial enrichment strategy
with regulatory focus. Observational data from both
the literature and at least seven individual datasets,
including biomarker data from several cohort stud-
ies (OPDC, ProBaND, CamPaIGN, and PPMI) and
clinical trials will be used to model disease progres-
sion similarly to the way ADNI and other data were
used to build and then confirm a hypothetical model
of disease progression in AD [9, 41, 42 ]. Success
of the proposed PD regulatory pathway will require
the implementation of PD data standards and the con-
struction of a data sharing mechanism of an integrated
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Fig. 1. Proposed Roadmap for building PD drug development tools with existing data. Proposed roadmap outlining a potential future path for
integrating global data from PD observational and clinical trials targeting early stages. Integration of diverse data from at least seven independent
clinical studies into a unified database will enable a regulatory path for use of biomarkers and quantitative disease progression models that serve
to streamline and derisk drug development of new therapies.
database to effectively utilize those data. The model
will enable simulation of PD progression trajectories
of different subpopulations, thus indicating particular
endophenotypes, which can then be used to optimize
entry criteria for clinical trials, improve the statistical
power and increase chances of success. The proposed
roadmap follows a path to enable regulatory decisions
with broad application to clinical trials. Furthermore,
enhanced data-sharing will catalyze novel discoveries
in PD research.
CONCLUSIONS
The need for a global database that integrates large
amounts of diverse data was identified as essential
to fuel progress in identifying indicators of pre-
clinical and early motor PD, which would enable the
development of pre-symptomatic disease modifying
treatments and improved symptomatic treatments.
The workshop aligned on interim steps toward the
eventual goal of building and achieving consensus on
precompetitive data sharing as a catalyst to advanc-
ing research for PD. One proposal is the regulatory
endorsement of new drug development tools, including
a clinical trial enrichment platform and a trial modeling
and simulation tool. This will require:
• Cataloging existing clinical and observational
datasets and the types of data within those datasets
that are relevant to the research question(s) being
posed.
• Developing and applying data standards that
will enable integration of data across multiple
datasets, including novel types of data such as that
collected from remote monitoring devices and
biosensors.
• Maximizing the use of existing data by establish-
ing acceptable guidelines for data sharing.
• Supporting the further development of new
biomarkers and assessment tools that will pro-
vide a better understanding of the phenotypic
variations of PD.
• Promote the implementation of new technologies
such as wearable devices into PD for enabling
personalized medicine.
• Promoting further collaboration across all
stakeholders.
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